GMABGenmabRunning, no new patients
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Diffuse Large B-Cell Lymphoma
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 72 (final count)
- Started
- Oct 8, 2022
- Main results expected
- Oct 13, 2025
- Fully finished
- Jun 14, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-13, no fading
Raw record changes
- none yet
Trial ID NCT07226752 · record last updated 2026-05-05 · checked 2026-11-09 15:47 UTC